Novartis AG ADR (NVS)vsGeneDx Holdings Corp. (WGS)
NVS
Novartis AG ADR
$146.03
+0.44%
HEALTHCARE · Cap: $277.42B
WGS
GeneDx Holdings Corp.
$40.77
+0.67%
HEALTHCARE · Cap: $1.20B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 12681% more annual revenue ($56.58B vs $442.68M). NVS leads profitability with a 23.9% profit margin vs -17.6%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
WGS
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-51.8%
Fair Value
$110.12
Current Price
$146.03
$35.91 premium
Margin of Safety
-54.0%
Fair Value
$59.37
Current Price
$40.77
$18.60 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
17.4% revenue growth
Areas to Watch
Grey zone — moderate risk
Expensive relative to growth rate
Revenue declined 0.7%
Earnings declined 9.3%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -30.4% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : WGS
The strongest argument for WGS centers on Revenue Growth. Revenue growth of 17.4% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, PEG Ratio, Revenue Growth.
Bear Case : WGS
The primary concerns for WGS are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
NVS profiles as a declining stock while WGS is a growth play — different risk/reward profiles.
WGS carries more volatility with a beta of 2.07 — expect wider price swings.
WGS is growing revenue faster at 17.4% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 29/100), backed by strong 23.9% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →GeneDx Holdings Corp.
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Sema4 Holdings Corp. The company is headquartered in Stamford, Connecticut.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?